axicabtagene ciloleucel


( Last Updated : May 11, 2022)
Generic Name:
axicabtagene ciloleucel
Project Status:
Pending
Therapeutic Area:
Large B-cell lymphoma
Manufacturer:
Gilead Sciences Canada Inc.
Call for patient/clinician input open:
Brand Name:
Yescarta
Project Line:
Reimbursement Review
Project Number:
PG0293-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma

Details


Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), who are candidates for autologous stem cell transplant (ASCT)
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Lymphoma
Indications:
The treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL)
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.